Dysphoria

Bio-K Plus Officially Launches New Line of Shelf-Stable Probiotic Capsules with Multi-Benefit Health Solutions and makes its Debut in the US Mass Channel

Retrieved on: 
Lunedì, Maggio 13, 2024
Sprouts, Taste, Body image, Food, Sprouts Farmers Market, Woman, Capsule, Disease, Health, CFU, Dysphoria, Human, ABS, Probiotic, Research, Farmer, Kerry Group, Temperature, Quality of life, Multimedia, Dietary supplement

This innovative line of specialized wellness features Bio-K+'s proprietary strains and/or scientifically supported extra ingredients for immune health, women's health, stress support and bowel support.

Key Points: 
  • This innovative line of specialized wellness features Bio-K+'s proprietary strains and/or scientifically supported extra ingredients for immune health, women's health, stress support and bowel support.
  • Moreover, they feature targeted release technology for proper delivery of probiotic bacteria in the gut.
  • The Advanced Bowel Support (ABS)† probiotic capsules contain 50 billion CFU per capsule of Bio-K+'s scientifically supported formula, studied for over 20 years.
  • Research indicates ABS helps with maintenance of quality of life score1*, helps normalize bowel habits and relieve occasional abdominal discomfort.†
    Recognizing the significant demand for women's health supplements,2 Bio-K+ introduces Women's Health† probiotic capsules.

Mindpath Health releases Daddy Issues: Understanding Attachment Trauma

Retrieved on: 
Mercoledì, Febbraio 21, 2024
DSM, Incidence, Anxiety, Woman, Caregiver, Mental health, Emotion, Love Is Blind, Emotional dysregulation, Friends, Impulsivity, Love, Parent, Life, Risk, Perception, Dysphoria, Fear, Anhedonia, Family, Chronic pain, Hypervigilance, Child, ADHD, Trauma, DSM-IV codes, Doctor of Psychology, Personality disorder, Depression, Nursing

A psychological name for daddy issues: attachment trauma

Key Points: 
  • A psychological name for daddy issues: attachment trauma
    Clearly, 'daddy issues' is not a clinical term, and you won't find it in the DSM.
  • At its core, 'daddy issues' is a label for something very clinical: attachment trauma.
  • Like many forms of trauma, attachment trauma can have real effects on your mental health .
  • Attachment trauma, or the effects of inconsistent or abusive parenting, shows up in several different insecure attachment styles developed by psychologist John Bowlby .

Rittenhouse Psychiatric Associates Expands Services With Hiring of Emily Bernstein, MD - Director of Women's Mental Health

Retrieved on: 
Martedì, Dicembre 12, 2023
Health, PMDD, Philadelphia Eagles, University, Menopause, Dysphoria, Piper, Associate, Mental health, Patient, Pregnancy, Psychiatry, MD, Crozer Health, Medical degree, Neurology, Mental, University of Pennsylvania, Nursing

PHILADELPHIA, Dec. 12, 2023 /PRNewswire/ -- Rittenhouse Psychiatric Associates is proud to announce the continued expansion of their 25-provider team and broadening of their women's mental health services, welcoming Emily Bernstein, MD to their roster of outpatient mental health experts. Dr. Bernstein's focus includes pregnancy treatment planning, postpartum care, premenstrual dysphoric disorder (PMDD) & psychiatric symptoms of menopause.

Key Points: 
  • PHILADELPHIA, Dec. 12, 2023 /PRNewswire/ -- Rittenhouse Psychiatric Associates is proud to announce the continued expansion of their 25-provider team and broadening of their women's mental health services, welcoming Emily Bernstein, MD to their roster of outpatient mental health experts.
  • Dr. Bernstein's focus includes pregnancy treatment planning, postpartum care, premenstrual dysphoric disorder (PMDD) & psychiatric symptoms of menopause.
  • "I'm very excited to join the team here at Rittenhouse Psychiatric Associates," expressed Bernstein.
  • Dr. Bernstein offers her services at Rittenhouse Psychiatric Associate's Paoli, Pennsylvania office and via telepsychiatry to all of Pennsylvania & New Jersey.

New Original Documentary "NO WAY BACK: The Reality of Gender-Affirming Care" to Receive a World Premiere Event at AMC Theatres Throughout the US - June 21, 4:30 and 7:30 PM

Retrieved on: 
Martedì, Giugno 13, 2023
LGBT, Sociology, Endocrinology, Depression, Autism spectrum, Capri Hollywood International Film Festival, Borderline personality disorder, DVD, Pediatrics, Anxiety, ADHD, Dysphoria, NO, Gender dysphoria, Patient, Dissociative identity disorder, PKS, LOS, Health, Mental health, PTSD, BACK, Nursing

LOS ANGELES, June 13, 2023 /PRNewswire/ -- How are today's youth being impacted by transitioning genders into their teens and young adult years? The new original documentary "NO WAY BACK," produced by lifelong California Democrats and LGBT activists, takes a non-religious, non-political, and non-ideological look on the subject of gender-affirmative medical practices, the risks and side effects of cross-sex hormones, surgeries, and the long-term health implications of gender medicalization. This "nuanced, compassionate, deeply researched and mild-mannered" documentary features five young people discussing the medical care they received for gender dysphoria, and how they subsequently realized they were given the wrong treatment. Twelve experts in pediatrics, mental health, sociology and endocrinology with decades of clinical practice (including an Oxford professor) examine the pros and cons of the current practices. The goal of "NO WAY BACK," which cites 45 academic medical studies and journalist articles, is to make a substantial contribution to the debate around medical transitioning for adolescents and young adults.

Key Points: 
  • This "nuanced, compassionate, deeply researched and mild-mannered" documentary features five young people discussing the medical care they received for gender dysphoria, and how they subsequently realized they were given the wrong treatment.
  • Twelve experts in pediatrics, mental health, sociology and endocrinology with decades of clinical practice (including an Oxford professor) examine the pros and cons of the current practices.
  • These patients have multiple mental co-morbidities (Autism, ADHD, PTSD, borderline personality disorder, adverse childhood experiences, sexual trauma).
  • Instead of giving a differential diagnosis, or a holistic treatment plan, the doctors quickly prescribe wrong-sex hormones on the 1st appointment.

Scilex, a Sorrento Company, Highlights Safety Data From Phase 1 Trial of SP-104, a Proprietary Low Dose Naltrexone for Fibromyalgia

Retrieved on: 
Mercoledì, Maggio 11, 2022
Sciatica, PALO, Failure, Safety, Dexamethasone, Anxiety, Quality of life, PHN, BCA, TRPV1, SEC, Technology, Combination company, Risk, Phase, Antibody, Stomach, Forward-looking statement, Postherpetic neuralgia, Pain, Company, Securities Act of 1933, Patient, Fast track (FDA), Naltrexone, Prospectus, Physician, FDA, RTX, Regulation of tobacco by the U.S. Food and Drug Administration, Nasdaq, SAN, Therapy, Capsule, Population, Private Securities Litigation Reform Act, Volunteering, Low back pain, Fibromyalgia, Time, Autoimmune disease, Hyperalgesia, NCT, Radiculopathy, Vaccine, Sale, FM, SP-104, Common, Acquisition, COVID-19, Sleep, Name, GLOBE, Form, Food, Combined, Proxy, Dysphoria, Cancer, Osteoarthritis, SP-102, Pharmacy, Chronic pain, Insomnia, Pharmaceutical industry, Security (finance)

SP-104 is a novel, proprietary, fixed dose, delayed burst release of low dose naltrexone hydrochloride, 4.5 mg, for treatment of fibromyalgia (FM).

Key Points: 
  • SP-104 is a novel, proprietary, fixed dose, delayed burst release of low dose naltrexone hydrochloride, 4.5 mg, for treatment of fibromyalgia (FM).
  • Prior investigational trials support the use and development of SP-104, delayed burst release naltrexone hydrochloride 4.5 mg, for FM.
  • Physicians currently use the commercially available high-dose tablets (naltrexone hydrochloride 50 mg) and have compounding pharmacies aliquot lower doses for patients.
  • RTX has been cleared for a Phase II trial for intractable pain associated with cancer and a Phase II trial in osteoarthritis patients.

Probing Pooch Severely Poisoned by Eating 600 Sleep Supplements

Retrieved on: 
Mercoledì, Gennaio 12, 2022
Numa, Rectum, Prescription, Light, Diazepam, Cyproheptadine, Seizure, Mouth, Poisoning, Dog, Veterinarian, Tablet, CNS, Dysphoria, Serotonin syndrome, Benzodiazepine, Database, Death, GI, Temperature, PETS, Time, Animal, Blood pressure, Anxiety, Serotonin, Phenobarbital, Sleep, Lab, Cat, Family, Child, Brain, Bird, Labrador, Toxicology, GiFT, Hunting, Medical device, Pharmaceutical industry, MAV

Mav had ingested up to 600 dietary sleep supplements and the rural veterinarian who was treating him was about to handle her first case of the rare but potentially deadly serotonin syndrome.

Key Points: 
  • Mav had ingested up to 600 dietary sleep supplements and the rural veterinarian who was treating him was about to handle her first case of the rare but potentially deadly serotonin syndrome.
  • While these supplements benefit many people, their increased popularity in homes has caused an increased danger for pets of accidental poisoning.
  • "Like medications, supplements can pose a severe threat to pets if accidentally ingested," said Dr. Renee Schmid, a senior veterinary toxicologist at Pet Poison Helpline.
  • "My son and his wife were visiting," explained Axthelm, "and she had brought a bottle of sleep supplements with her and left them in their room when we went out.

Global Gender Dysphoria Epidemiology Insight Report 2020: Treatment, Unmet Needs, Patient Population, Background and Overview

Retrieved on: 
Martedì, Dicembre 22, 2020
Psychiatric diagnosis, Mind, Gender identity, Personal life, Psychology, Gender dysphoria, Mood disorders, Dysphoria

This 'Gender Dysphoria - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Gender Dysphoria epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Key Points: 
  • This 'Gender Dysphoria - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Gender Dysphoria epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • The publisher's gender dysphoria epidemiology report gives a thorough understanding of the condition by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis.
  • Moreover, the report covers detailed information on the gender dysphoria epidemiology scenario in seven major countries (US, EU5, and Japan).
  • The gender dysphoria report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
    The gender dysphoria report and model provide an overview of the global trends of gender dysphoria in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

Global Gender Dysphoria Epidemiology Insight Report 2017-2030 - ResearchAndMarkets.com

Retrieved on: 
Mercoledì, Dicembre 16, 2020
General Health, Health, Mental health, Other Health, Psychiatric diagnosis, Mind, Gender identity, Personal life, Psychology, Gender dysphoria, Mood disorders, Dysphoria

This 'Gender Dysphoria - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Gender Dysphoria epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Key Points: 
  • This 'Gender Dysphoria - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Gender Dysphoria epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • The publisher's gender dysphoria epidemiology report gives a thorough understanding of the condition by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis.
  • Moreover, the report covers detailed information on the gender dysphoria epidemiology scenario in seven major countries (US, EU5, and Japan).
  • The gender dysphoria report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
    The gender dysphoria report and model provide an overview of the global trends of gender dysphoria in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

Gender Dysphoria Market Insight, Epidemiology and Market Forecast, 2017-2030 - ResearchAndMarkets.com

Retrieved on: 
Giovedì, Novembre 12, 2020
Health, Pharmaceutical, Mind, Gender identity, Psychiatric diagnosis, Psychology, Gender dysphoria, Dysphoria, Articles

The "Gender Dysphoria - Market Insight, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gender Dysphoria - Market Insight, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This 'Gender Dysphoria - Market Insights, Epidemiology, and Market Forecast - 2030' report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of gender dysphoria in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The gender dysphoria market report provides analysis regarding current treatment practices, market share of the individual therapies, and historical, current, and forecasted gender dysphoria market size from 2017 to 2030, segmented by seven major markets.
  • Gender dysphoria epidemiology is segmented by the total prevalent gender dysphoria cases, the gender-specific prevalence of gender dysphoria, and comorbidities associated with gender dysphoria.